Tempus AI, Inc. (NASDAQ:TEM) Short Interest Update

Tempus AI, Inc. (NASDAQ:TEM) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 8,730,000 shares, an increase of 42.2% from the December 15th total of 6,140,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 3.7 days. Approximately 17.8% of the company’s stock are sold short.

Tempus AI Stock Down 0.6 %

NASDAQ:TEM traded down $0.21 during mid-day trading on Thursday, hitting $34.71. 2,488,269 shares of the company’s stock traded hands, compared to its average volume of 4,020,976. The firm has a 50 day moving average of $47.24 and a two-hundred day moving average of $47.17. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the transaction, the executive vice president now owns 246,085 shares in the company, valued at approximately $10,431,543.15. This represents a 17.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 865,041 shares of company stock valued at $35,917,673 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently modified their holdings of TEM. First Horizon Advisors Inc. bought a new stake in Tempus AI in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at about $67,000. Sandia Investment Management LP bought a new stake in shares of Tempus AI in the second quarter valued at about $136,000. Vestor Capital LLC acquired a new stake in Tempus AI during the third quarter worth about $153,000. Finally, Stifel Financial Corp bought a new position in Tempus AI during the third quarter valued at about $218,000. 24.22% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on TEM shares. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Finally, Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.